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Pptimal Timing for the Initiation of
re-Treatment With 300 mg Clopidogrel
efore Percutaneous Coronary Intervention
teven R. Steinhubl, MD,* Peter B. Berger, MD,† Danielle M. Brennan, MS,‡ Eric J. Topol, MD,§
or the CREDO Investigators
exington, Kentucky; Durham, North Carolina; and Cleveland, Ohio
OBJECTIVES This study sought to determine the optimal timing of a 300-mg clopidogrel loading dose
before percutaneous coronary intervention (PCI) in patients enrolled in the Clopidogrel for
the Reduction of Events During Observation (CREDO) trial.
BACKGROUND A loading dose of clopidogrel before a PCI has become relatively commonplace, although the
data supporting this practice are limited and sometimes conflicting.
METHODS Patients were randomized to receive either 300 mg clopidogrel or a matching placebo adminis-
tered a minimum of 3 h and a maximum of 24 h before PCI. The primary 28-day combined end
point was death, myocardial infarction, or urgent target vessel revascularization. Linear splines
were used to summarize the effect of the time of pre-treatment as a continuous variable.
RESULTS A total of 1,762 patients were evaluated. For patients randomized to placebo, there was no
relationship between the duration of pre-treatment and the occurrence of the primary end
point, whereas longer durations of pre-treatment in patients randomized to clopidogrel were
associated with improved outcomes. The event rates diverged maximally at 24 h. The
difference in outcomes between placebo and clopidogrel pre-treated patients was not
significant until15 h pre-treatment, with a 58.8% (p 0.028) reduction in the primary end
point in patients pre-treated with clopidogrel 15 h compared with placebo.
CONCLUSIONS When a 300-mg loading dose of clopidogrel is used, little benefit is obtained compared with
just 75 mg at the time of the PCI when the treatment duration is 12 h. In patients
pre-treated for longer durations, the optimal duration seems to approach 24 h. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.047Cardiol 2006;47:939–43) © 2006 by the American College of Cardiology Foundation
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Tlthough the clinical benefit of the early initiation of
hienopyridine treatment for the prevention of peri-
rocedural thrombotic complications in patients undergoing
ercutaneous coronary intervention (PCI) has yet to be
efinitively proven in placebo-controlled clinical trials, the
olume of data supporting such a benefit has led to its
idespread acceptance into clinical practice (1–5). However,
he optimal duration of pre-treatment remains unclear, espe-
ially with the commonly used 300-mg dose. Much of this
onfusion centers around the wide variability in duration of
re-treatment—ranging from hours to days—reported in clin-
cal studies supporting the benefit of pre-treatment.
Ex-vivo determination of the degree of inhibition of
denosine diphosphate-induced platelet aggregation using
ight transmission aggregometry has been most commonly
sed to identify the pharmacodynamics of clopidogrel, with
he time between treatment initiation and the achievement
f maximal inhibition of platelet aggregation assumed to
eflect the time required to achieve maximal clinical efficacy.
ased on several of these studies, it was therefore initially
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ccepted October 10, 2005.hought that 300 mg given at least three hours before a PCI
ould supply maximal, or at least near maximal, clinical
enefit (6,7). However, in the Clopidogrel for the Reduc-
ion of Events During Observation (CREDO) trial, in
hich patients were randomized to 300 mg clopidogrel or
atching placebo, no significant difference in the 28-day
ombined end point of death, myocardial infarction (MI),
r urgent target vessel revascularization (UTVR) was ob-
erved (5). Subsequent analysis using pre-specified durations
f pre-treatment of 3 to 6 h, 6 to 12 h, or 12 to 24 h before
CI found that only those patients pre-treated with clopi-
ogrel for 6 h experienced a decrease in event rates
ompared with placebo, with a 37% relative risk reduction in
he 28-day end point that was not quite statistically signif-
cant (p  0.051). Based on these clinical data and ex vivo
ggregometry, six hours of pre-treatment with 300 mg of
lopidogrel has been suggested to be adequate to achieve the
ull clinical benefit of this loading dose.
The goal of this study was to examine the duration of
re-treatment with clopidogrel as a continuous variable and
dentify the optimal duration of pre-treatment with a
00-mg loading dose of clopidogrel in terms of the occur-
ence of ischemic complications.
ETHODS
he CREDO trial methodology has been published in
etail elsewhere (5). Briefly, the CREDO trial enrolled
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Clopidogrel Pre-Treatment Timing March 7, 2006:939–43,116 patients (1,053 assigned to clopidogrel and 1,063 to
lacebo) referred for planned PCI or likely to require PCI.
everal important exclusion criteria were an ST-segment
levation MI within 24 h, a planned staged procedure,
reatment with a platelet glycoprotein (GP) IIb/IIIa antag-
nists within 7 days, or clopidogrel or ticlopidine within 10
ays. The present analysis includes only those 1,815 patients
ho underwent a PCI shortly after enrollment, during the
ndex catheterization.
All patients were randomized to a 300-mg clopidogrel
ral loading dose or to matching placebo 3 to 24 h
re-procedure in a double-blind fashion. The use of GP
Ib/IIIa antagonists was at the discretion of the operator but
ould only be pre-specified at the time of enrollment or
iven as bail-out during the PCI procedure. Both groups
ere treated with clopidogrel 75 mg and aspirin 325 mg
aily for 28 days after the PCI. The present analysis is only
f the relationship between duration of pre-treatment and
utcome at 28 days.
he 28-day end points. The primary end point was the
omposite of death, MI, or UTVR at 28 days, the defini-
ions of which have been previously published (5). Major
leeding was defined as intracranial bleeding or bleeding
ssociated with a decrease in hemoglobin of more than 5 g/dl.
ll outcome events were adjudicated by a blinded Clinical
vents Committee.
tatistical analysis. Categorical variables are displayed as
requencies and percentages, and comparisons were made
ith chi-square testing. Continuous variables appear as
edians with interquartile ranges and were compared using
ilcoxon rank-sum tests. Kaplan-Meier methods are used
n time-to-event analyses. Linear splines were used to
ummarize the effect of time of pre-treatment. It created
wo independent regression lines from a linear regression
odel that were joined at one point, or knot, because the
lopes of the time of pre-treatment changed direction at that
not. Statistical analyses were performed with SAS version
.2 (SAS Institute Inc., Cary, North Carolina).
ESULTS
f 2,116 patients randomized, 1,815 underwent PCI dur-
ng their index procedure. The timing of study drug
reatment was able to be analyzed in 1,762 of these 1,815
atients, and they comprise the study population. The mean
uration of pre-treatment was 9.8 h. As previously reported,
andomization to clopidogrel pre-treatment was associated
ith a non-significant 18.5% relative risk reduction in the
Abbreviations and Acronyms
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous coronary intervention
UTVR  urgent target vessel revascularization8-day combined end point (5).
t
Among the patients randomized to placebo, no relation-
hip was found between the duration of pre-treatment and
he occurrence of the primary 28-day combined end point of
eath, MI, or UTVR (Fig. 1). On the other hand, patients
andomized to receive a 300-mg loading dose of clopidogrel
ad a strong relationship between the duration of pre-
reatment and occurrence of the primary end point. Unex-
ectedly, no separation between the placebo and treatment
rm curves was seen until after 10 to 12 h of pre-treatment,
nd this difference did not become statistically significant
ntil after 15 h of pre-treatment. The log odds of the 28-day
ombined end point continued to decrease out to the
aximal duration of pre-treatment in this study, 24 h.
Pertinent baseline and procedural characteristics in pa-
ients randomized to placebo, patients randomized to clo-
idogrel pre-treatment whose therapy was initiated 15 h
efore PCI, and patients randomized to clopidogrel pre-
reatment whose therapy was initiated 15 h before PCI
re shown in Table 1. No significant differences were noted
xcept for less use of GP IIb/IIIa antagonists in those
atients pre-treated with clopidogrel 15 h compared with
hose pre-treated 15 h.
The incidence of the 28-day end point was similar in
hose patients randomized to the placebo arm and those
andomized to the clopidogrel arm who had therapy initi-
ted 15 h before PCI (Fig. 2). The relative risk reduction
n those pre-treated with clopidogrel from 15 h compared
ith the placebo arm was 58.8% (p  0.028). This relative
isk reduction associated with 15 h of clopidogrel pre-
reatment before PCI was unchanged when only those
atients in the placebo (n  206) and treatment (n  202)
rms who had been pre-treated15 h were compared (9.7%
s. 3.5%; relative risk reduction, 66.6%; 95% confidence
nterval, 19.2% to 86.2%; p  0.011). When all pertinent
aseline and procedural characteristics were evaluated in a
ultivariate analysis, clopidogrel pre-treatment for 15 h
igure 1. Relationship between the duration of study drug treatment
efore percutaneous coronary intervention and log odds of the primary
ombined end point of death, myocardial infarction (MI), and urgent
arget vessel revascularization (UTVR). Dotted line  placebo; Solid line
clopidogrel.
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March 7, 2006:939–43 Clopidogrel Pre-Treatment Timingemained a significant predictor of the 28-day end point
odds ratio, 0.72; p  0.043).
Glycoprotein IIb/IIIa inhibitors were used in45% of all
atients, and at similar rates in those randomized to placebo
nd to active treatment. Whether or not a patient received
GP IIb/IIIa antagonist did not significantly influence the
enefit of clopidogrel pre-treatment for 15 h (p value for
nteraction  0.90), although the relative risk reduction
ssociated with prolonged clopidogrel pre-treatment tended
able 1. Baseline and Procedural Characteristics
Placebo
(n  915)
edian age in yrs (IQR) 62.0 (54, 71)
edian body mass index (IQR) 29.9 (26.1, 32.6)
omen 29.3
ypertension 69.3
iabetes mellitus 25.7
yperlipidemia 78.2
moking within last yr 30.6
eripheral vascular disease 8.2
erebrovascular disease 6.3
revious myocardial infarction 34.7
revious percutaneous coronary intervention 29.9
revious coronary artery bypass graft 16.3
ongestive heart failure 9.5
ndication for procedure
Unstable angina 53.6
Recent myocardial infarction 13.5
Stable angina 28.4
Silent ischemia 4.5
ercutaneous coronary intervention success
(50% residual stenosis)
96.9
therectomy 4.6
alloon angioplasty alone 6.7
lycoprotein IIb/IIIa antagonist used 43.3
Prespecified 17.7
Bailout 19.1
ll values percentages unless otherwise noted. *Nonparametric test.
IQR  intraquartile range.
igure 2. Kaplan-Meier curves of the occurrence of the primary combined
nd point of death, myocardial infarction (MI), and urgent target vessel
evascularization (UTVR) in patients randomized to placebo, patients ran-
omized to receive a 300-mg loading dose of clopidogrel that was initiated
15 h before percutaneous coronary intervention, and patients randomized to
eceive a 300-mg loading dose of clopidogrel that was initiated 15 h before
ercutaneous coronary intervention. For pre-treatment 15 h versus placebo,
 0.018; for pre-treatment 15 h versus 15 h, p  0.033; and for
lacebo versus pre-treatment 15 h, p  0.72.
2
oo be greater in those patients who did not receive a GP
Ib/IIIa antagonist (Fig. 3).
The incidence of major and minor bleeding at 28 days
as not significantly different between the placebo arm,
hose patients pre-treated 15 h, and those patients pre-
reated 15 h (Table 2).
ISCUSSION
he results of this analysis from the CREDO trial have
mportant clinical implications and call into question some
ong-held assumptions regarding the optimal use of thien-
pyridines in the setting of a PCI.
dogrel Pre-Treatment
<15 h (n  645)
Clopidogrel Pre-Treatment
>15 h (n  202) p Value
61.8 (53, 71) 61.4 (53, 70) 0.61*
30.4 (26.5, 32.9) 29.7 (26.2, 32.4) 0.77*
28.2 28.2 0.94
67.3 68.3 0.69
28.0 27.7 0.58
76.2 81.5 0.28
32.8 41.1 0.67
10.1 7.5 0.33
5.7 5.5 0.82
32.8 41.1 0.10
26.0 28.2 0.25
16.3 13.8 0.66
8.1 6.9 0.41
53.4 47.0 0.22
14.8 16.3 0.52
26.0 30.2 0.42
5.8 6.4 0.39
96.3 98.2 0.46
5.9 5.0 0.51
5.9 3.0 0.13
49.8 42.6 0.03
18.6 14.9 0.48
19.5 22.3 0.60
igure 3. Plot of the odds ratios (OR) with 95% confidence intervals of theClopi8-day primary end point for clopidogrel versus placebo based on duration
f pre-treatment and glycoprotein (GP) IIb/IIIa antagonist use.
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Clopidogrel Pre-Treatment Timing March 7, 2006:939–43It is not exactly known what percentage of patients
ndergoing a non-urgent PCI are currently pre-treated with
lopidogrel. During the CREDO trial, the single most
ommon reason for a potentially eligible patient being
xcluded from randomization was the desire of the patient’s
hysician to pre-treat with a thienopyridine. Recent data
rom the CRUSADE registry, which include only acute
oronary syndrome patients, confirm that the use of early
lopidogrel is increasing over the last several years (8). Our
ndings suggest that many pre-treated patients are not
eceiving any protection from PCI-related thrombotic
vents if they are receiving 300 mg clopidogrel12 h before
he procedure, and may require at least 24 h of pre-
reatment to achieve maximal protection.
One intriguing finding from this analysis is the apparent
iscrepancy between ex vivo studies of the pharmacodynam-
cs of a clopidogrel loading dose and the timing of its clinical
enefit. In one of the most extensive studies to date of the
harmacodynamics of a 300-mg loading dose of clopi-
ogrel, 15 different measures of platelet function were
tudied in 100 patients, 75 of whom received 300 mg
lopidogrel between 3 and 24 h before a PCI and 25
atients who received 75 mg at the time of the procedure
6). Patients receiving a loading dose achieved similar levels
f platelet inhibition pre-PCI, irrespective of timing of the
oading dose that was not matched by those patients who
eceived 75 mg at the time of PCI until 5 days after the
CI procedure. Other pharmacodynamic studies of 300 mg
lopidogrel have for the most part mirrored these results,
ith the majority of platelet inhibition, although not max-
mal inhibition, being achieved within the first three to six
ours of treatment (9,10).
Although it is clear that the clinical benefit of all
ntiplatelet agents, including aspirin, thienopyridines, and
he GP IIb/IIIa antagonists (parenteral and oral), cannot
olely be predicted by their ability to inhibit agonist-induced
latelet aggregation, platelet aggregometry is still considered
he gold standard for identifying the pharmacodynamic
roperties of antiplatelet agents. However, we are aware of
o other measure of the antiplatelet (or any other) effects of
lopidogrel that mimic the clinic findings described here.
urther studies might elucidate other potential effects of
hienopyridines not related to their direct effect on the
latelet P2Y12 receptor that could possibly follow a phar-
acodynamic course more consistent with the clinical findings
rom this study. Decreases in monocyte and endothelial tissue
actor activity (11,12), endothelial passivation (13,14), vascular
mooth cell effects (15), or anti-inflammatory effects, some
Table 2. 28-Day Bleeding Events
Placebo
(n  915)
Clopidogrel
<15 h
Major bleeding, n (%) 16 (1.7) 15
Minor bleeding, n (%) 13 (1.4) 14ossibly related to direct effects on lymphocytes (16), are iome possible mechanisms that may better correlate with
he clinical data.
A second interesting finding from this analysis was that
hen adequate pre-treatment was not achieved, the dose of
lopidogrel used seemed to have little impact on 28-day
vent rates. Surprisingly, patients receiving 300 mg clopi-
ogrel, even when given up to 10 h before the PCI, had
dentical outcomes as did those patients who received only
5 mg at the time of the PCI. When the interventional
ardiologists switched from routinely using ticlopidine to
sing clopidogrel in patients with stents, one reason was the
bility to achieve a more rapid onset of action with a
00-mg loading dose. It was assumed that this faster
nset after stenting would lead to fewer adverse events.
e did not find this to be the case in the CREDO trial.
ur findings are consistent with those found in the
lopidogrel Aspirin Stent International Cooperative
tudy (CLASSICS) trial, the only blinded trial of ticlo-
idine versus clopidogrel (75 mg and 300 mg) in stent-
reated patients (17).
In a recent analysis of the Intracoronary Stenting and
ntithrombotic Regimen–Rapid Early Action for Coronary
reatment (ISAR-REACT) trial, in which all patients
eceived a 600-mg loading dose of clopidogrel between 2
nd 24 h before PCI, no relationship was found between the
uration of pre-treatment and clinical events (18). Although
here was no clopidogrel-placebo arm in this study, these
esults suggest that unlike with a 300-mg loading dose, a
00-mg loading dose is able to achieve its maximal clinical
enefit within 2 h. This faster onset of action of a 600-mg
oading dose compared with 300 mg would help explain the
ower event rates in a recent trial comparing these two
oading regimens initiated 4 to 8 h before a PCI (19).
tudy limitations. This is a post-hoc analysis of a prospec-
ive, randomized, blinded trial. Although a post-hoc anal-
sis is the only manner in which the duration of pre-
reatment can be analyzed as a continuous variable, which
dds considerable power to the analysis and allows one to
dentify the point at which the curves begin to separate, it
lso raises the possibility of a finding attributable to chance.
eyond the broad limits of 3 to 24 h before a planned PCI,
he actual duration of pre-treatment was at the discretion
f the operator. However, because treatment was blinded
nd the decision regarding when the study drug should be
nitiated was made before the patients received the study
rug, unaccounted-for biases would be unlikely to have
reatment
645)
Clopidogrel Pre-Treatment
>15 h (n  202)
p
Value
3 (1.5) 0.64
4 (2.0) 0.52Pre-T
(n 
(2.3)
(2.2)nfluenced the results and conclusions of this study.
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March 7, 2006:939–43 Clopidogrel Pre-Treatment TimingONCLUSIONS
hese data suggest that when a 300-mg loading dose of
lopidogrel is used, little benefit is obtained compared with
ust 75 mg of clopidogrel at the time of the PCI when
reatment duration is 12 h before the procedure. In
hose patients pre-treated for longer durations, the optimal
uration is still not clear, but seems to approach 24 h. Based
n these results, along with the results of the analysis from
he ISAR-REACT trial (18), for pre-treatment with a
lopidogrel loading dose to be of any benefit before a PCI it
hould be initiated at least 15 to 24 h beforehand if a dose
f 300 mg is used. In situations in which longer durations of
re-treatment are not possible, 600 mg may be used when
iven at least two hours before PCI.
eprint requests and correspondence: Dr. Steven R. Steinhubl,
ivision of Cardiovascular Medicine, 900 South Limestone, 326
harles T. Wethington Building, Lexington, Kentucky 40536-
200. E-mail: Steinhubl@uky.edu.
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